Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients.
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients.
复制标题
维持性血液透析患者对辉瑞 BNT162b2 疫苗加强剂的体液反应。
DOI：
10.1159/000521676
复制
发表时间：
2022
影响因子：
4.2
通讯作者：
中科院分区：
文献类型：
--
作者：
冠状病毒疾病与维持性血液透析（MHD）患者的发病率和死亡率增加相关。最近在接种疫苗的人群中发生的突破性感染导致一些当局建议对5-8个月前完全接种疫苗的患者进行加强剂量。我们的目的是评估MHD患者加强接种BNT 162 b2疫苗后的体液应答。该研究包括102名接种了2剂BNT 162 b2（Pfizer-BioNTech）疫苗的MHD患者。第三剂（加强剂）被推荐给我们中心的所有MHD患者，并给予那些选择接受它的人，导致加强组和对照组没有接受加强剂。通过检测是否存在抗核衣壳抗体（SARS-CoV-2）或PCR阳性排除既往暴露。我们评估了加强剂量前后的体液反应。在加强组的66名患者中，65名患者（98.5%）产生了阳性抗体应答，从472.7 ± 749.5降至16，336.8 ± 15，397.3，而对照组持续下降（695.7 ± 642.7降至383.6 ± 298.6），p < 0.0001。未报告显著不良反应。先前的抗体滴度与加强剂量后的IgG水平呈正相关。营养不良-炎症标志物与体液反应之间存在显著相关性。几乎所有的MHD患者在加强剂量后都产生了实质性的体液应答，这显著高于MHD患者在单独给药2次后报告的水平。需要进一步的研究和观察来确定确切的时间和给药方案。
Coronavirus disease is associated with increased morbidity and mortality in maintenance hemodialysis (MHD) patients. Recent breakthrough infection in vaccinated people has led some authorities to recommend a booster dose for patients fully vaccinated 5–8 months ago. We aimed to assess the humoral response of MHD patients following a booster dose with the BNT162b2 vaccine. The study included 102 MHD patients vaccinated with 2 doses of the BNT162b2 (Pfizer-BioNTech) vaccine. A third dose (booster) was recommended to all MHD patients in our center and was given to those who opted to receive it, resulting in a booster group and a control group that did not receive the booster. Previous exposure was excluded by testing for the presence of the anti-nucleocapsid antibody (SARS-CoV-2) or positive PCR. We assessed the humoral response before and after the booster dose. Of 66 patients in the booster group, 65 patients (98.5%) developed a positive antibody response, from 472.7 ± 749.5 to 16,336.8 ± 15,397.3, as compared to a sustained decrease in the control group (695.7 ± 642.7 to 383.6 ± 298.6), p < 0.0001. No significant adverse effects were reported. Prior antibody titers were positively correlated to IgG levels following the booster dose. There was a significant association between malnutrition-inflammation markers and the humoral response. Almost all MHD patients developed a substantial humoral response following the booster dose, which was significantly higher than levels reported for MHD patients following administration of 2 doses alone. Further studies and observations are needed to determine the exact timing and dosing schedule.
登录
查看更多内容
影响因子：
7.3
作者：
Pereira B;Xu XN;Akbar AN
通讯作者：
Akbar AN
影响因子：
25.7
作者：
Rabinowich L;Grupper A;Baruch R;Ben-Yehoyada M;Halperin T;Turner D;Katchman E;Levi S;Houri I;Lubezky N;Shibolet O;Katchman H
通讯作者：
Katchman H
影响因子：
8.8
作者：
Grupper, Ayelet;Rabinowich, Liane;Katchman, Helena
通讯作者：
Katchman, Helena
DOI：
10.1056/nejmoa2109072
发表时间：
2021-10-14
期刊：
The New England journal of medicine
影响因子：
--
作者：
Bergwerk M;Gonen T;Lustig Y;Amit S;Lipsitch M;Cohen C;Mandelboim M;Levin EG;Rubin C;Indenbaum V;Tal I;Zavitan M;Zuckerman N;Bar-Chaim A;Kreiss Y;Regev-Yochay G
通讯作者：
Regev-Yochay G
影响因子：
5.4
作者：
Pinti, Marcello;Appay, Victor;Campisi, Judith;Frasca, Daniela;Fulop, Tamas;Sauce, Delphine;Larbi, Anis;Weinberger, Birgit;Cossarizza, Andrea
通讯作者：
Cossarizza, Andrea